Trial Search Results
Mixed Chimera Allogeneic Transplantation From Matched Unrelated Donors For The Treatment Of Multiple Myeloma
The purpose of the study is to determine the toxicity and feasibility of non-myeloablative allogeneic hematopoietic cell transplants for multiple myeloma from unrelated donors.
Stanford is currently not accepting patients for this trial.
- Procedure: Autologous followed by non-myeloablative allogeneic transplantation
Inclusion Criteria:a) Multiple myeloma which is responsive to therapy. Eligible patients
may have early or relapsed disease. Patients must have Stage II-III disease or have
progression after initial treatment of Stage I disease. Patients who have relapsed
following autologous transplantation may be eligible for this protocol.
b) Age <= 60 years. c) No prior therapy which would preclude the use of low-dose total body
d) Patients must have their pathology reviewed and the diagnosis confirmed at Stanford
University Medical Center. Patients with smoldering multiple myeloma, monoclonal gammopathy
of unknown significance, or amyloidosis will be excluded from this study.
e) Patients must have a Karnofsky performance status > 70%. f) DLCO >= 60% predicted. g)
ALT and AST must be < 2X normal. Total bilirubin less than 2 mg/dl. h) Serum creatinine <
2.0 or 24-hour creatinine clearance >= 50 ml/min. i) Patients must be HIV negative. j)
Pregnant or lactating women will not be eligible to participate. k) Patients must provide
signed, informed consent. Exclusion Criteria:a) Severe psychological or medical illness b)
Patients who have undergone prior allogeneic hematopoietic cell transplantation will not be
eligible for this study.
c) Patients who have an HLA-identical sibling donor will be excluded
Ages Eligible for Study
18 Years - 60 Years
Genders Eligible for Study